Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR-Reference-Cited by-同舟云学术

Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR

Published:2023-07 Issue:7 Volume:31 Page:2089-2104
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Kokalaki Evangelia^ORCID,Ma Biao,Ferrari Mathieu,Grothier Thomas,Hazelton Warren,Manzoor Somayya,Costu Eren,Taylor Julia,Bulek Anna,Srivastava Saket,Gannon Isaac,Jha Ram,Gealy Rosalind,Stanczuk Lukas,Rizou Tatiana,Robson Mathew,El-Kholy Mohamed,Baldan Vania,Righi Matteo,Sillibourne James,Thomas Simon,Onuoha Shimobi,Cordoba Shaun,Pule Martin^ORCID

Funder

University College London Hospitals Biomedical Research Centre

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference67 articles.

1. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date;Park;Blood,2016

2. CD19 chimeric antigen receptor T cell therapy for haematological malignancies;Ghorashian;Br. J. Haematol.,2015

3. Chimeric antigen receptor therapy;June;N. Engl. J. Med.,2018

4. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy;Sotillo;Cancer Discov.,2015

5. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy;Gardner;Blood,2016

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma;Frontiers in Oncology;2024-04-22

2. The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B‐cell malignancies;British Journal of Haematology;2024-02-16

3. CD19/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL;Blood;2024-01-11

4. Dual CAR-T Cells Targeting CD19 and CD37 Are Effective in Target Antigen Loss B-cell Tumor Models;Molecular Cancer Therapeutics;2023-12-05

5. Financial risk tolerance: A review and research agenda;European Management Journal;2023-12